Molecular Diagnosis & Therapy

, Volume 21, Issue 2, pp 225–232 | Cite as

Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer

Adis Diagnostic Profile


Epi proColon® 2.0 CE is a blood-based test designed to aid in the early detection of colorectal cancer. The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy. Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with high clinical sensitivity and specificity in pivotal case-control studies. The sensitivity of the test did not appear to be affected by the tumour location or by patient age or gender. In addition, limited data suggest that Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with higher sensitivity and generally similar specificity to that of the faecal immunochemical test, and with higher sensitivity and specificity to that of the guaiac-based faecal occult blood test (statistical data not available). In an observational study, most patients who refused colonoscopy for screening accepted a non-invasive test option as an alternative, and preferred Epi proColon® 2.0 CE over a stool-based test. Large prospective trials of Epi proColon® 2.0 CE in a screening setting will be required to further elucidate the cost-effectiveness of the test. Nevertheless, currently available data suggests that Epi proColon® 2.0 CE has the potential to be a sensitive and convenient screening option for patients refusing screening by colonoscopy.


  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Accessed 9 Jan 2017.
  3. 3.
    Toth K, Sipos F, Kalmar A, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One. 2012;7(9):e46000.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    American Cancer Society. Colorectal cancer facts and figures 2014–2016. Accessed 9 Jan 2017.
  5. 5.
    McPhail S, Johnson S, Greenberg D, et al. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112:S108–15.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30(5):830–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54(2):414–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Momparler RL. Cancer epigenetics. Oncogene. 2003;22:6479–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Toth K, Wasserkort R, Sipos F, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9(12):e115415.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Epigenomics Inc. Epi proColon 2.0 CE (European version IFU 0009GB, rev 6)—instructions for use. 2015. Accessed 9 Jan 2017.
  12. 12.
    Epigenomics AG. Epigenomics AG: life technologies to supply crucial components for second-generation colorectal cancer blood test [media release]. 2011.
  13. 13.
    Epigenomics AG. Epigenomics announces the European launch of Epi proColon® 2.0 CE [media release]. 2011.
  14. 14.
    Epigenomics Inc. Epi proColon (US version IFU 0008, rev 10)—instructions for use. 2016. Accessed 9 Jan 2017.
  15. 15.
    Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One. 2010;5(2):e9061.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3(11):e3759.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Potter NT, Hurban P, White MN, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014;60(9):1183–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Johnson DA, Barclay RL, Mergener K, et al. Plasma septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014;9(6):e98238.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–25.CrossRefPubMedGoogle Scholar
  20. 20.
    DeVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Duffy MJ, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Park MJ, Choi KS, Lee YK, et al. A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol. 2012;47(4):461–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn. 2016;18(4):535–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2016;. doi:10.1016/j.ctarc.2016.12.004.Google Scholar
  25. 25.
    Epigenomics AG. Epigenomics and BioChain announce the inclusion of their proprietary blood-based septin9 test in the Chinese screening guideline for colorectal cancer [media release]. 2015.
  26. 26.
    Chinese Society of Digestive Endoscopy of the Chinese Medical Association, Oncologic Endoscopic Committee of the Chinese Anti-Cancer Association. Chinese early colorectal cancer screening and endoscopic diagnosis and treatment guidelines (Beijing, 2014). Chin J Dig Endosc. 2015;32(6):341–60.Google Scholar
  27. 27.
    von Karsa L, Patnick J, Segnan N, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45:51–9.CrossRefGoogle Scholar
  28. 28.
    Sung JJY, Ng SC, Chan FKL, et al. An updated Asia Pacific consensus recommendations on colorectal cancer screening. Gut. 2015;64:121–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Ladabaum U, Allen J, Wandell M, et al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomark Prev. 2013;22(9):1567–76.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations